Heparin attenuates low-dose streptozotocin-induced immune diabetes in mice and inhibits the beta-cell binding of T-splenocytes in vitro.
Five low doses (40 mg.kg-1.day-1) of streptozotocin were given to CD-1 mice to induce "immune" diabetes with insulitis. T-splenocytes (L3T4+ and Lyt2+) from streptozotocin-treated mice were previously reported to display in vitro an increased binding for Beta cells, preceding the onset of hyperglycaemia and of insulitis. Since heparin inhibits lymphocyte traffic, displays anti-adhesive properties, and attenuates some cell-mediated immune diseases, we have investigated the effects of heparin and N-desulphated heparin: 1) in vivo on low-dose streptozotocin-induced diabetes and insulitis, and 2) in vitro on the increased binding of T-splenocytes from streptozotocin-treated mice to rat insulinoma (RINm5F) cells. Daily subcutaneous low doses (5 micrograms or 10 micrograms) of heparin induced a delay in onset and a reduction of the severity of hyperglycaemia and insulitis (p less than 0.01), and reduced the incidence of diabetes (p less than 0.01). Similar effects were obtained with 5 micrograms daily doses of N-desulphated heparin devoid of anticoagulant activity. In contrast, lower (1 microgram) or higher (200 micrograms) doses of heparin were ineffective. Heparin (10 micrograms) did not modify the "toxic" diabetes induced by a single high dose (200 mg/kg) of streptozotocin. On the other hand, heparin dose-dependently (0.1 microgram/ml to 500.0 micrograms/ml) inhibited the increased binding of splenocytes from streptozotocin-injected mice to RIN cells as compared to splenocytes from control mice. This in vitro anti-adhesive effect was detected when either splenocytes or RIN cells were pretreated with heparin before their co-incubation, and was also obtained with N-desulphated heparin.(ABSTRACT TRUNCATED AT 250 WORDS)
Saï
P
P
Laboratoire d'Immunologie du Diabète, Faculté de Médecine, Nantes, France.
Pogu
S
S
Ouary
M
M
D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002448:Cell Adhesion / Q000187:drug effects; D002460:Cell Line; D002478:Cells, Cultured; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D007515:Islets of Langerhans / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D008297:Male; D051379:Mice; D008815:Mice, Inbred Strains; D013154:Spleen / Q000276:immunology; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology*
D001786:Blood Glucose; D006493:Heparin